Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues

The medical treatment of non-small-cell lung cancer (NSCLC) has progressively changed since the introduction of “targeted therapy”. The development of one of these molecular drug categories, e. g., the epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) selective inhibitors, such as the ora...

Descripción completa

Detalles Bibliográficos
Autores principales: Bencardino, K., Manzoni, M., Delfanti, S., Riccardi, A., Danova, M., Corazza, G. R.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780603/
https://www.ncbi.nlm.nih.gov/pubmed/17551677
http://dx.doi.org/10.1007/s11739-007-0002-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780603/
https://www.ncbi.nlm.nih.gov/pubmed/17551677
http://dx.doi.org/10.1007/s11739-007-0002-5

Ejemplares similares